摘要: The mathematical modeling concepts developed by Robert Dedrick and his colleagues, subsequent preclinical evaluation, provided a strong framework upon which to build clinical investigative program examining intraperitoneal (IP) chemotherapy as management approach in advanced ovarian cancer. These efforts suggested the type of antineoplastic agents that should be explored, patient populations more likely benefit, limitations potential toxicities this novel strategy.